InMed Pharmaceuticals develops small molecule drug candidates for Alzheimer's, eye disease and a skin condition. It last closed at $17.50 on Nov 17, down 11.93% on the day. MTRI reports earnings on Wed, Feb 10, 2027. The average 12-month price target from 3 analysts is $31.00 (+77.1% from the last close), with a high of $33.00 and a low of $30.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print totaling $2.7M, the largest $2.7M.
Each firm's latest rating on MTRI in the past 90 days
Average 12-month target
$31.00
▲ 77.1% upside
Based on 3 analysts who set a price target on MTRI in the past 90 days. The average target is $31.00, with a high of $33.00 and a low of $30.00, compared with the last close of $17.50.
Low $30.00Avg $31.00High $33.00
Blue marker: last close $17.50
Highest target$33.00
Average target$31.00
Lowest target$30.00
Latest rating changes
WedbushInitiated
Nov 13Buy$33
JefferiesInitiated
Nov 10Buy$30
StifelInitiated
Nov 10Buy$30
Date
Firm
Action
Rating
Price target
Nov 13
Wedbush
Initiated
Buy
$33
Nov 10
Jefferies
Initiated
Buy
$30
Nov 10
Stifel
Initiated
Buy
$30
Loading…
Whale Options Flow
90D
No whale options trades in MTRI in the last 90 days.
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MTRI is in one of them and how their past MTRI trades turned out.
InMed Pharmaceuticals is a drug development company based in Vancouver, Canada. It develops small molecule drug candidates that act on the CB1 and CB2 receptors of the endocannabinoid system, which is found throughout the body. Its pipeline targets Alzheimer's disease, dry macular degeneration (AMD) and epidermolysis bullosa, a skin condition. Most of its programs are at the preclinical stage, while its cannabinol cream has completed a Phase 2 trial in epidermolysis bullosa.